Meftal Spas

# Meftal spas ## Overview - **Classification**: Combination product containing a **Non-Steroidal Anti-Inflammatory Drug (NSAID)** (Mefenamic Acid) and an **Anticholinergic/Antispasmodic** (Dicyclomine HCl). - **Mechanism**: Mefenamic Acid inhibits cyclooxygenase (COX-1 & COX-2), reducing prostaglandin synthesis for pain and inflammation. Dicyclomine HCl is an anticholinergic that blocks muscarinic receptors and has direct smooth muscle relaxant effects, reducing muscle spasms. ## Primary Indications 1. **Dysmenorrhea**: Relief of spasmodic pain associated with menstruation. 2. **Intestinal Colic/Spasms**: Management of spasmodic pain in the gastrointestinal tract. 3. **Biliary/Renal Colic**: Adjunctive relief of pain due to smooth muscle spasms. ## Adult Dosing ### Standard Dosing **Dysmenorrhea / Intestinal Colic** - **Dose**: **1 tablet** (typically containing Mefenamic Acid **250 mg** + Dicyclomine HCl **10 mg**) - **Frequency**: Up to **3 times daily** - **Route**: Oral - **Duration**: Short-term use, typically **3-5 days** for acute pain. ### Dose Adjustments - **Renal Impairment**: **Caution**; reduce dose or avoid in moderate to severe impairment (CrCl <30 mL/min) due to Mefenamic Acid. Dicyclomine excretion also affected. - **Hepatic Impairment**: **Caution/Contraindicated** in severe impairment; monitor liver function. Both components are metabolized by the liver. - **Elderly Patients**: Use with **extreme caution**; lower doses may be required due to increased sensitivity to adverse effects (especially anticholinergic effects and renal/GI risks). Avoid if possible. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **Contraindicated**. - **Special Notes**: Dicyclomine is absolutely contraindicated in infants <6 months due to severe risk of respiratory depression, apnea, seizures, and SIDS. Mefenamic acid is also generally not recommended. ### Infants (1-12 months) - **Dose**: **Contraindicated**. - **Special Notes**: Dicyclomine is absolutely contraindicated in infants <6 months. High risk of severe anticholinergic effects. ### Children (1-12 years) - **Dose**: **Generally not recommended** for routine use due to the dicyclomine component's risk profile in young children. - **Maximum**: Not established for this combination in young children. - **Special Notes**: If used off-label in older children (>6-12 years) under strict medical supervision for severe spasms, single-ingredient products are preferred. The combination is typically for adolescents/adults. ### Adolescents (13-18 years) - **Dose**: May follow adult dosing: **1 tablet** (Mefenamic Acid **250 mg** + Dicyclomine HCl **10 mg**). - **Frequency**: Up to **3 times daily**. - **Maximum**: **3 tablets/day** (Mefenamic Acid **750 mg**/day, Dicyclomine HCl **30 mg**/day). - **Special Notes**: Consider weight; lower dose if significantly underweight. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to mefenamic acid, dicyclomine, or other NSAIDs (e.g., aspirin triad: asthma, rhinitis, nasal polyps). - **Absolute**: **Infants < 6 months** (due to dicyclomine). - **Absolute**: Active peptic ulcer disease, GI bleeding, inflammatory bowel disease. - **Absolute**: Severe renal or hepatic impairment. - **Absolute**: Obstructive uropathy, paralytic ileus, severe ulcerative colitis, glaucoma, myasthenia gravis. - **Absolute**: History of coronary artery bypass graft (CABG) surgery (NSAID component). - **Relative**: Cardiovascular disease, uncontrolled hypertension, asthma (non-NSAID induced). ### Common Adverse Effects - **Very Common (>10%)**: Dry mouth (dicyclomine). - **Common (1-10%)**: Nausea, vomiting, abdominal pain, diarrhea, constipation, dizziness, blurred vision (dicyclomine). Headache, heartburn (mefenamic acid). - **Serious but Rare**: Gastrointestinal bleeding/perforation, acute kidney injury, severe allergic reactions (anaphylaxis), Stevens-Johnson syndrome, cardiovascular thrombotic events (NSAID). Respiratory depression, psychosis (dicyclomine overdose). ### Key Drug Interactions - **Anticoagulants (e.g., Warfarin)**: Increased bleeding risk with Mefenamic Acid. - **Lithium**: Increased lithium levels with Mefenamic Acid. Monitor levels. - **Methotrexate**: Increased methotrexate toxicity. Avoid concomitant use. - **Antihypertensives (e.g., ACE inhibitors, Diuretics)**: Reduced antihypertensive effect, increased renal toxicity risk with Mefenamic Acid. - **Other Anticholinergics (e.g., TCAs, Antihistamines)**: Additive anticholinergic effects (dry mouth, blurred vision, urinary retention). - **Corticosteroids**: Increased risk of GI adverse events (bleeding). ## Monitoring & Follow-up - **Before Treatment**: Assess GI history, renal/hepatic function, blood pressure. - **During Treatment**: - Monitor for signs of GI bleeding (black stools, vomiting blood). - Monitor renal function (creatinine, GFR) in patients at risk or with prolonged use. - Monitor blood pressure periodically. - Watch for changes in vision (blurred vision, increased intraocular pressure in glaucoma patients). - Observe for urinary retention, especially in elderly or patients with prostate issues. - **Clinical Signs**: Report persistent GI upset, unusual bleeding/bruising, blurred vision, difficulty urinating, or severe dizziness/confusion immediately. ## Clinical Pearls - 💡 **Short-term Use**: Best used for acute, short-term relief of spasmodic pain due to NSAID and anticholinergic side effect profiles. - 💡 **Take With Food**: To minimize gastrointestinal irritation and adverse effects. - 💡 **Anticholinergic Effects**: Counsel patients about common anticholinergic effects like dry mouth, blurred vision, and constipation. Advise caution with driving. - 💡 **Hydration**: Maintain adequate hydration to reduce the risk of renal adverse effects from Mefenamic Acid. - 💡 **Pediatric Warning**: Emphasize this combination product is **not for infants** due to dicyclomine's serious risks. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.